Phuturdex › Diseases › Chronic progressive multiple sclerosis
Drugs in development · updated 30 October 2026
Chronic progressive multiple sclerosis: drugs in development
As of 30 October 2026 there are 35 active clinical trials (recruiting or ongoing, phases I–III) on 39 drugs for chronic progressive multiple sclerosis. 16 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OrelabrutinibICP-022 | III | 2 | NCT07067463 |
| Fenebrutinib | III | 1 | NCT04544449 |
| TolebrutinibCenrifki® | III | 1 | NCT06372145 |
| KYV-101 | II | 3 | NCT06384976 |
| C-CAR168 | I–II | 1 | NCT07825389 |
| CTX112 | I–II | 1 | NCT07804004 |
| Foralumab Nasal | II | 1 | NCT06292923 |
| NG01 | II | 1 | NCT06961383 |
| RO7268489 | II | 1 | NCT07282574 |
| SUN-627 | II | 1 | NCT07840326 |
| SYS6020 | I–II | 1 | NCT07756268 |
| TRX319 | I–II | 1 | NCT07477639 |
| ABA-101 | I | 1 | NCT06566261 |
| CTA313 | I | 1 | NCT07783269 |
| Quercetin | I | 1 | NCT07270120 |
| RHuPH20 | I | 1 | NCT07667322 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OcrelizumabOcrevus | III | 7 | NCT04544449 |
| Cladribine2-chlorodeoxyadenosine, Mavenclad® | II–III | 2 | NCT04695080 |
| MethylprednisoloneMethylprednisolon, Methylprenisolone | III | 2 | NCT04688788 |
| RemibrutinibLOU064, Rhapsido® | III | 2 | NCT07225504 |
| RituximabRuxience, Rituxan | III | 2 | NCT04688788 |
| AcetaminophenParacetamol, APAP | III | 1 | NCT04688788 |
| FexofenadineChildren'S Allegra Hives®, Children'S Allegra Allergy® | III | 1 | NCT04688788 |
| TeriflunomideAubagio®, Teriflunomide Viatris (previously Teriflunomide Mylan)® | III | 1 | NCT06372145 |
| BendamustineBendamustin, Bedamustine | I–II | 1 | NCT07477639 |
| CilostazolPletal® | I–II | 1 | NCT03109288 |
| Clemastine FumarateTavist-1®, Tavist® | I–II | 1 | NCT05359653 |
| DantroleneRyanodex®, Dantrium® | I–II | 1 | NCT03109288 |
| IndapamideLozol® | II | 1 | NCT07765212 |
| LeucovorinFolinic acid, l-leucovorin | I–II | 1 | NCT03109288 |
| MetforminRiomet Er®, Glumetza® | II | 1 | NCT05893225 |
Sorted by most advanced phase and number of active trials. Showing 15 of 23 drugs.
All 39 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Nervous System Diseases 39 drugs
- Immune System Diseases 54 drugs
- Demyelinating disease 6 drugs
- Autoimmune disease 94 drugs
- Autoimmune disease of the nervous system 21 drugs
- Multiple sclerosis 93 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D020528 “Multiple Sclerosis, Chronic Progressive”.